June 27 (Reuters) - Verona Pharma's therapy for

treating a chronic lung disease will be sold in the U.S. at a

wholesale price of $2,950 per month, the U.K.-based company said

on a conference call on Thursday.

The U.S. health regulator's assent on Wednesday for the

therapy, branded as Ohtuvayre, provides a new inhaled

non-steroidal treatment for chronic obstructive pulmonary

disease.